Gender-Specific Differences in Concentrations of Biochemical Parameters in Persons over the Age of 90

Paulina Zabielska 1, Sylwia Wieder-Huszla 2,*, Izabela Gutowska 3, Anna Lubkowska 4, Anna Knyszyńska 4 and Anna Jurczak 2

1 Department of Social Medicine and Public Health, Chair of Social Medicine, Pomeranian Medical University in Szczecin, Zolnierska Str. 48, 71-210 Szczecin, Poland; paulina.zabielska@pum.edu.pl
2 Department of Clinical Nursing, Pomeranian Medical University in Szczecin, Zolnierska Str. 48, 71-210 Szczecin, Poland; anna.jurczak@pum.edu.pl
3 Department of Human Nutrition and Metabolomics, Pomeranian Medical University in Szczecin, Broniewskiego Str. 24, 71-460 Szczecin, Poland; izagut@poczta.onet.pl
4 Department of Functional Diagnostics and Physical Medicine, Pomeranian Medical University in Szczecin, Zolnierska Str. 54, 71-210 Szczecin, Poland; anna.lubkowska@pum.edu.pl (A.L.); anna.knyszynska@pum.edu.pl (A.K.)

* Correspondence: sylwia.huszla@pum.edu.pl; Tel.: +48-914-800-910

Received: 26 April 2019; Accepted: 29 May 2019; Published: 30 May 2019

Abstract: The ageing process is a phenomenon leading to an emergence of a web of interrelated biological processes producing significant changes in the human body. The aim of the paper was to analyse gender-specific differences with regard to selected biochemical parameters in longevity. The study was conducted in Poland in 2017. The study population comprised of long-lived individuals, both living at home and staying at residential care homes. There were 90 people of both genders (69 women and 21 men) aged between 90 and 103 years (mean = 92.36; SD = 2.98). The biochemical markers of longevity in the studied patients were identified by assessing their pro-inflammatory and anti-inflammatory status in various metabolic aspects. The analysis of biochemical variables revealed numerous statistically significant differences, both in the study group as a whole and between the genders. The ageing process is extremely complex, but understanding it will allow for a real intervention in life extension. Research into the processes involved in ageing and longevity will enable a better understanding of the mechanisms responsible for them, and to enjoy those processes in good health.

Keywords: longevity; gender differences; inflammation

1. Introduction

In recent years, with the progress of civilisation and breakthroughs in science, life expectancy has been increasing around the world. This phenomenon may be attributed mainly to the development of new medical technologies and more effective treatment methods, but also to the advent of healthy lifestyles and active ageing measures which have been widely promoted since late 20th century [1]. Over the past few decades, in many countries there has been a marked increase in the number of longevous people, aged 90 years and more (especially centenarians), and in the coming years this population is expected to grow. Centenarians as a group account for the most spectacular growth, also within the Polish society. According to Statistics Poland (GUS), in 2007 there were 1390 centenarians in 2013–3196, and according to the forecasts by 2035 the number of people aged 100 years and over is expected to exceed nine thousand. Further, the nonagenarian population in Poland is projected to nearly double by 2035 [2]. Ageing, followed by old age, is one of the least known stages of the human life cycle.
life cycle. Changes taking place in that period occur in many dimensions. Therefore, it makes sense to engage in a multi-faceted analysis of the ageing process, carried out by interdisciplinary teams with expertise in biomedical science as well as social studies [3]. The exceedingly individual nature of this process cannot be denied, and the length of human life varies widely, not only across individuals and populations, but also genders. On a global scale, women live on average 6 years longer than men, and whose ageing process generally tends to be accelerated [4].

As life expectancy increases in developed countries, there are some serious risks related to the growing numbers of elderly people with cognitive impairment and dementia in the overall population. Such a situation is associated with a decline in physical activity, brain structural integrity and secretion of growth factors, such as the growth hormone (GH) and insulin-like growth factor-1 (IGF-I) [5]. The guidelines on the use of GH take into account patient age and gender. Women require higher doses of the hormone used over a longer duration to obtain the same IGF-1 response as men. For elderly patients, GH dosage is lower, and the period of therapy is longer than in the younger population [6].

Age is directly associated with the incidence of cardiovascular incidents, where elevated levels of homocysteine are a predictive factor. Therefore, measuring the level of that amino acid is vital in the prevention and treatment of cardiovascular disease [7,8]. As an additional risk factor in post-menopausal women, the decline in oestrogen levels impairs the regenerative capacity of the cardiovascular system, and at a later stage leads to age-related microvascular rarefaction [9].

Reduced physical activity in post-menopausal women contributes to persistent inflammation, which is perceived as endothelial dysfunction and vascular alterations [10]. It is also associated with excessive accumulation of adipose tissue, which secretes elevated amounts of pro-inflammatory cytokines, including tumour necrosis factor alpha (TNF-α), interleukin-1 beta (IL-1β) and interleukin-6 (IL-6) [9]. Studies have also indicated a correlation between the levels of pro-inflammatory cytokines and symptoms of depression in the elderly population. Inflammation plays a key role in the onset and progression of atherosclerosis. Therefore, the measurement of inflammatory markers in blood serum is useful in risk assessment for cardiovascular disease. The most commonly used inflammatory markers include: IL-6, C-reactive protein (CRP) and TNF-α. There is little data on the differences in IL-6, CRP and TNF-α levels between men and women [10]. Elevated CRP was also observed to be associated with a depressed mood in people over the age of 65 [11]. Elevated blood levels of pro-inflammatory markers, such as CRP and IL-6, are found in patients with chronic obstructive pulmonary disease (COPD) [12].

Recent studies demonstrated that adipose tissue serves as a source of additional molecules that integrate metabolism, immune response and normal vascular function. Leptin is structurally similar to IL-6 which is responsible for some physiological actions, such as food intake and angiogenesis, at the same time sustaining a proinflammatory environment. Likewise, resistin modulates several metabolic and inflammatory pathways and plays an important role in the development of atherosclerosis. On the other hand, adiponectin features prominently in the maintenance of endothelial function, displaying anti-inflammatory, and antiatherogenic properties [9,13]. In the elderly, a high IL-6 level is associated with increased mortality, mainly due to neoplastic processes [14].

The circulating inflammatory markers related to CRP and fibrinogen are associated with the risk of ischemic heart disease and stroke [15,16]. Fibrinogen is a marker of both hypercoagulability and inflammation. The role of subclinical inflammation in the development of atherosclerosis and as a contributing factor in acute coronary episodes has been proven long ago [17]. Available research findings also show fibrinogen to be a stronger risk factor in the development of atherosclerosis than cholesterol. Fibrinogen levels are correlated with the severity of calcification and progression of lesions in coronary arteries. High fibrinogen levels in people with unstable coronary heart disease enhance the risk of a heart attack and death, while persistent elevated levels after a heart attack are an unfavourable prognostic factor [18]. Increased concentrations of fibrinogen are observed in stable chronic obstructive pulmonary disease (COPD), and during the acute stage of the disease, it is accompanied by an upswing in serum levels of IL-6. Therefore, it is highly likely that increased levels
of the above parameters are associated with accelerated development of vascular atherosclerosis in this patient group [19].

Gender and gender-specific quantitative and qualitative differences in hormone levels unquestionably impact on the function of the body as a whole, and also determine its response to various stimuli. On the other hand, ageing and the associated disorders in hormone synthesis, particularly with respect to sex hormones, affect metabolism as a whole. Having regard to the above, the aim defined for our study was to analyse gender-specific differences with regard to selected biochemical parameters in longevity.

2. Materials and Methods

2.1. The Study Group

The study was conducted in Poland in 2017, in two voivodeships (provinces)—West Pomerania (Zachodniopomorskie) and Masovia (Mazowieckie). The people inhabiting Masovia are for the most part indigenous to Poland, whereas West Pomerania is characterised by a population with a migrant background, due to the resettlements after 1945. The study population comprised long-lived individuals, both living at home and staying at residential care homes. There were 90 people of both genders (69 women and 21 men) aged between 90 and 103 years (mean = 92.36; SD = 2.98). Women accounted for 76.7% of the studied population (mean age = 92.59; SD = 3.15), and men 23.3% (mean age = 91.57; SD = 2.20).

Fasting blood samples were collected from each patient (at least 8 h since the last meal): 7.5 mL of blood from an available vein into a Vacutainer clot activator tube. The blood was centrifuged (1500 g/15 min/room temperature), and the obtained serum was used to determine the levels of selected biochemical parameters.

All patients were thoroughly informed about the scope and objectives of the study and gave their written consent for participation. The study was approved by the Bioethics Committee of the Pomeranian Medical University (no. KB-0012/47/16).

The biochemical markers of longevity in patients were identified by assessing their pro-inflammatory and anti-inflammatory status in various metabolic aspects:

- determination of concentrations of proinflammatory (IL-6, IL-1, TNF-α, CRP, fibrinogen) and anti-inflammatory (L-10, TGF-β1) factors;
- determination of signalling pathway factors: insulin, IGF-1 (insulin-like growth factor 1);
- determination of the concentration of adipokines, hormones produces by adipose tissue: adiponectin, leptin and resistin;
- evaluation of hormone levels: growth hormone–releasing hormone (GHRH, somatocrinin), thyroid-stimulating hormone (TSH, thyrotropin), growth hormone (GH), cortisol, gonadotropins: follicle-stimulating hormone (FSH) and luteinizing hormone (LH);
- determination of activity of antioxidant enzymes and glutathione (reduced and oxidised forms) in plasma and in isolated red blood cells.

2.2. Statistical Analysis

Statistical analyses were performed using the IBM SPSS Statistics v.21 suite (IBM, Armonk, NY, USA). To compare groups in terms of the distribution of nominal variables, Pearson’s chi-squared test was employed, and the comparison of means in two independent groups was used for quantitative variables. Due to the significant difference in the size of the groups subject to comparison, the non-parametric Mann-Whitney U test was chosen. A multiple linear regression model was also used. The statistical significance cutoff was set at $p < 0.05$, and $p < 0.1$ was adopted as a marker of a statistical trend. The tables were made in APA format.
3. Results

Following the analysis of the results of biochemical examinations in the study group taking into account the patients’ sex, no statistically significant differences were found in the selected biochemical parameters (Table 1). Differences between men and women of borderline statistical significance were found only in two of the analysed blood serum parameters. The average levels of HGH (human growth hormone) and TNF-α were higher in women ($p = 0.067$ and $p = 0.071$).

Table 1. Elements of the statistical description of the analysed variables according to the participants’ gender.

| Variable         | n  | Mean | Min–Max | Q1–Q3 | $p$  |
|------------------|----|------|---------|-------|------|
| Age              |    |      |         |       |      |
| Total            | 90 | 92.00| 89–103  | 90–94 | -    |
| Woman            | 69 | 92.00| 89–103  | 90–94 | 0.228|
| Man              | 21 | 92.00| 89–96   | 90–93 |      |
| CRP [mg/L]       |    |      |         |       |      |
| Total            | 90 | 7.31 | 0.74–46.29 | 2.96–12.88 | - |
| Woman            | 69 | 7.24 | 0.75–46.29 | 3.09–12.21 | 0.670|
| Man              | 21 | 7.37 | 0.74–44.39 | 2.55–13.86 |      |
| Cortisol [µg/mL]|    |      |         |       |      |
| Total            | 89 | 0.16 | 0.04–0.46 | 0.1312–0.1871 | - |
| Woman            | 68 | 0.15 | 0.06–0.44 | 0.1312–0.1948 | 0.575|
| Man              | 21 | 0.17 | 0.04–0.22 | 0.1205–0.1866 |      |
| FSH [mLU/mL]     |    |      |         |       |      |
| Total            | 90 | 59.12| 0.86–154.1 | 15.18–105.7 | - |
| Woman            | 69 | 69.33| 0.86–154.1 | 15.62–113.1 | 0.189|
| Man              | 21 | 36.87| 3.86–150  | 14.9–84.1 |      |
| Insulin [µLU/mL]|    |      |         |       |      |
| Total            | 90 | 18.27| 1.76–142.3 | 9.318–43.67 | - |
| Woman            | 68 | 17.52| 1.76–117.5 | 8.641–41.25 | 0.338|
| Man              | 21 | 19.98| 2.32–142.3 | 10.98–47.42 |      |
| HGH [ng/mL]      |    |      |         |       |      |
| Total            | 90 | 1.05 | 0.5–102  | 0.5062–2.097 | - |
| Woman            | 69 | 1.12 | 0.5–102  | 0.5062–2.795 | 0.067|
| Man              | 21 | 0.80 | 0.5–4.833 | 0.5–1.046 |      |
| LH [ng/mL]       |    |      |         |       |      |
| Total            | 90 | 8.47 | 0.32–39.54 | 2.282–14.85 | - |
| Woman            | 69 | 9.43 | 0.32–28.61 | 2.571–15.72 | 0.114|
| Man              | 21 | 5.19 | 0.32–39.54 | 1.488–10.63 |      |
| Resistin [ng/mL]|    |      |         |       |      |
| Total            | 90 | 8.18 | 2.7–21.63 | 5.9724–10.8591 | - |
| Woman            | 69 | 8.30 | 2.8–21.63 | 6.5772–10.8591 | 0.465|
| Man              | 21 | 7.46 | 2.7–16.42 | 4.8321–9.7629 |      |
| GHRH [pg/mL]     |    |      |         |       |      |
| Total            | 88 | 137.55| 13.42–2460 | 64.26–284.4 | - |
| Woman            | 67 | 170.50| 13.42–2460 | 75.56–305 | 0.107|
| Man              | 21 | 92.47| 17.67–686.6 | 58.09–176.1 |      |
| Adiponectin [ng/mL]|   |      |         |       |      |
| Total            | 90 | 15,014.85| 1727.01–48,422 | 8379.3–20,398 | - |
| Woman            | 69 | 15,066.00| 3089.77–43,958 | 10,443.9–20,016.7 | 0.663|
| Man              | 21 | 14,728.10| 1727.01–48,422 | 5995.4–24,942.6 |      |
| GSH [Umol/L]     |    |      |         |       |      |
| Total            | 90 | 6.72 | 4.51–44.7 | 6.074–9.179 | - |
| Woman            | 69 | 6.68 | 4.81–44.7 | 6.059–8.806 | 0.275|
| Man              | 21 | 6.78 | 4.51–42.91 | 6.302–21.94 |      |
| Variable        | n  | Mean | Min–Max   | Q1–Q3     | p     |
|-----------------|----|------|-----------|-----------|-------|
| GPx [ng/mL]     |    |      |           |           |       |
| Total           | 90 | 41.28| 13.2–247.7| 36.98–63.14| -     |
| Woman           | 69 | 41.03| 13.2–247  | 37.53–58.03| 0.437 |
| Man             | 21 | 42.31| 25.49–247.7| 35.53–138.1|       |
| CAT [ng/mL]     |    |      |           |           |       |
| Total           | 90 | 56.27| 30.3–511.3| 48.32–77.48| -     |
| Woman           | 69 | 56.47| 30.3–511.3| 49.1–75.42 | 0.910 |
| Man             | 21 | 54.00| 36.3–485.9| 47.26–233.6|       |
| GST [ng/mL]     |    |      |           |           |       |
| Total           | 90 | 8.46 | 5.34–67.09| 7.277–11.63| -     |
| Woman           | 69 | 8.37 | 5.34–65.03| 7.277–11.28| 0.399 |
| Man             | 21 | 8.78 | 6.02–67.09| 7.474–31.71|       |
| GSSG [μmol/L]   |    |      |           |           |       |
| Total           | 90 | 2.76 | 1.46–15.44| 2.448–3.902| -     |
| Woman           | 69 | 2.82 | 1.46–15.44| 2.502–3.503| 0.719 |
| Man             | 21 | 2.52 | 1.92–15.38| 2.305–9.052|       |
| R-GSSG [ng/mL]  |    |      |           |           |       |
| Total           | 90 | 24.77| 15.9–445.7| 20.62–36.42| -     |
| Woman           | 69 | 24.20| 15.9–396.4| 20.62–33.59| 0.532 |
| Man             | 21 | 25.00| 15.9–445.7| 20.62–109.8|       |
| Homocysteine [nmol/mL] |    |      |           |           |       |
| Total           | 90 | 18.46| 2.8–56.53 | 16.13–21.87| -     |
| Woman           | 69 | 18.42| 2.8–56.53 | 16.13–21.43| 0.616 |
| Man             | 21 | 18.68| 12.4–54.16| 16.13–33.23|       |
| TNF-α [pg/mL]   |    |      |           |           |       |
| Total           | 90 | 8.48 | 1.23–69.06| 6.399–12.08| -     |
| Woman           | 69 | 8.85 | 1.23–69.06| 6.78–12.46 | 0.071 |
| Man             | 21 | 7.22 | 2.40–17.72| 5.02–11.32 |       |
| IL-1α [pg/mL]   |    |      |           |           |       |
| Total           | 88 | 102.00| 1.12–102  | 102–102   | -     |
| Woman           | 67 | 102.00| 1.12–102  | 102–102   | 0.648 |
| Man             | 21 | 102.00| 1.20–102  | 10.19–102 |       |
| IL-6 [pg/mL]    |    |      |           |           |       |
| Total           | 90 | 27.84| 3.13–668.8| 13.2–85.72| -     |
| Woman           | 69 | 27.16| 3.13–668.8| 14.63–54.24| 0.806 |
| Man             | 21 | 29.86| 3.13–474.6| 13.2–102  |       |
| SOD [ng/mL]     |    |      |           |           |       |
| Total           | 90 | 37.44| 22.1–133.1| 33.09–49.06| -     |
| Woman           | 69 | 37.16| 22.2–133.1| 31.92–46.53| 0.262 |
| Man             | 21 | 40.39| 22.1–131.8| 34.18–72.69|       |
| IGF-1 [ng/mL]   |    |      |           |           |       |
| Total           | 90 | 94.72| 27.06–175.4| 75.05–117.4| -     |
| Woman           | 69 | 95.05| 27.06–175.4| 78.83–115.6| 0.305 |
| Man             | 21 | 92.40| 35.93–156.6| 63.23–117.4|       |
| IL-1ß [pg/mL]   |    |      |           |           |       |
| Total           | 90 | 101.00| 1.07–1355 | 101–101   | -     |
| Woman           | 69 | 101.00| 1.07–1355 | 101–101   | 0.643 |
| Man             | 21 | 101.00| 34.5–101  | 101–101   |       |
| IL-10 [pg/mL]   |    |      |           |           |       |
| Total           | 89 | 3.11 | 1.6–631.7 | 1.6–22.98 | -     |
| Woman           | 68 | 2.79 | 1.6–631.7 | 1.6–23.3  | 0.726 |
| Man             | 21 | 4.39 | 1.6–80.12 | 1.6–15.27 |       |
| TGF-β1 [pg/mL]  |    |      |           |           |       |
| Total           | 90 | 372,000.00| 8565–12,6180| 29,328–46,650| -     |
| Woman           | 69 | 36,750.00| 8565–70,470| 28,971–45,960| 0.171 |
| Man             | 21 | 41,310.00| 26,598–12,6180| 31,920–30,850|       |
| Fibrinogen [μg/mL] |    |      |           |           |       |
| Total           | 90 | 40.89| 4.19–41.22| 40.81–41.05| -     |
| Woman           | 69 | 40.89| 5.31–41.22| 40.81–41.05| 0.507 |
| Man             | 21 | 40.89| 4.385–41.14| 40.81–41.05|       |
The Spearman rank correlation analysis of biochemical variables revealed numerous statistically significant differences, both in the study group as a whole and between the genders. The tables present only such correlations for which significance was found in the general group and/or one of the genders (Tables 2–7).

Table 2. The Spearman rank correlation analysis for insulin, including selected variables in the general group, men and women.

| Variable | Cortisol | HGH | Adiponectin | IL-1α |
|----------|----------|-----|-------------|-------|
| Insulin  |          |     |             |       |
| Total    | −0.333   | −0.236 | −0.247 | 0.176 |
|          | (0.001)  | (0.025) | (0.019) | (0.100) |
| Woman    | −0.238   | −0.200 | −0.195 | 0.283 |
|          | (0.050)  | (0.100) | (0.109) | (0.020) |
| Man      | −0.721   | −0.376 | −0.436 | −0.083 |
|          | (0.000)  | (0.093) | (0.048) | (0.720) |

HGH—human growth hormone; IL-1α-interleukin-1 alpha.

Table 3. The Spearman rank correlation analysis for C-reactive protein (CRP) and HGH, including selected variables in the general group, men and women.

| Variable | Resistin | LH | FSH | GSSG | TNF-α |
|----------|----------|----|-----|------|-------|
| CRP      |          |    |     |      |       |
| Total    | 0.253    | −0.343 | −0.314 | 0.132 | 0.242 |
|          | (0.016)  | (0.001) | (0.003) | (0.214) | (0.022) |
| Woman    | 0.475    | −0.421 | −0.443 | −0.053 | 0.347 |
|          | (0.000)  | (0.000) | (0.000) | (0.664) | (0.003) |
| Man      | −0.382   | −0.117 | 0.161 | 0.562 | −0.114 |
|          | (0.088)  | (0.613) | (0.486) | (0.008) | (0.624) |

| Variable | Resistin | LH | IGF-1 | GHRH | Adiponectin |
|----------|----------|----|------|------|-------------|
| HGH      |          |    |      |      |             |
| Total    | 0.240    | 0.064 | 0.226 | 0.775 | 0.400 |
|          | (0.023)  | (0.547) | (0.032) | (0.000) | (0.000) |
| Woman    | 0.215    | −0.072 | 0.126 | 0.757 | 0.334 |
|          | (0.076)  | (0.558) | (0.301) | (0.000) | (0.005) |
| Man      | 0.324    | 0.456 | 0.468 | 0.734 | 0.682 |
|          | (0.152)  | (0.038) | (0.032) | (0.000) | (0.001) |

LH—luteinizing hormone; FSH—follicle-stimulating hormone; GSSG—oxidized glutathione; GHRH—growth hormone-releasing hormone.

With respect to insulin, its serum levels are statistically negatively correlated with the concentrations of cortisol, HGH and adiponectin in the general group, and none of these relationships were found in the women’s group. Women are however, predisposed to a positive and statistically significant correlation between serum levels of insulin and IL-1α (Table 2).

With regard to serum CRP levels, a higher number of statistically significant correlations was found in women. Importantly, a decline in LH and FSH levels in older women was observed to cause a significant increase in CRP. In turn, serum HGH levels in older men exhibit a higher number of significant correlations with the biochemical parameters selected for analysis (LH, IGF-1, GHRH, adiponectin), all of them positive. The correlation between serum HGH and GHRH levels (growth hormone-releasing hormone) seems to be particularly significant in women (Table 3), as they were also found to have a significant positive dependence between GHRH and adiponectin (Table 5).
Table 4. Spearman rank correlation analysis for luteinizing hormone (LH) and homocysteine, including selected variables in the general group, men and women.

| Variable | FSH  | HGH  | Resistin | GSH  | GPx  | CAT  | GST  | IL-6 | SOD  | IGF-1 |
|----------|------|------|----------|------|------|------|------|------|------|-------|
|          | R(p) | R(p) | R(p)     | R(p) | R(p) | R(p) | R(p) | R(p) | R(p) | R(p)  |
| Total    | 0.866| 0.064| −0.144   | 0.145| 0.163| 0.123| 0.180| 0.180| −0.184| 0.129| 0.239 |
|          | (0.000)| (0.547)| (0.175) | (0.174)| (0.124)| (0.249)| (0.089)| (0.083)| (0.226)| (0.023)| |
| LH       | 0.838| −0.072| −0.265   | 0.297| 0.344| 0.257| 0.269| 0.269| −0.283| 0.267| 0.163 |
| Woman    | (0.000)| (0.558)| (0.028)| (0.013)| (0.004)| (0.033)| (0.025)| (0.019)| (0.026)| (0.182)| |
| Man      | 0.839| 0.456| 0.226    | −0.229| −0.329| −0.251| −0.005| 0.098| −0.312| 0.476|       |
|          | (0.000)| (0.038)| (0.324)| (0.318)| (0.145)| (0.272)| (0.982)| (0.674)| (0.168)| (0.029)| |
| Homocysteine | 0.088| −0.232| 0.799    | 0.748| 0.632| 0.817| 0.621| 0.790| 0.242| 0.789|       |
| Total    | (0.410)| (0.030)| (0.000)| (0.000)| (0.000)| (0.000)| (0.000)| (0.000)| (0.021)| (0.000)| |
| Woman    | 0.247| −0.173| 0.767    | 0.692| 0.752| 0.824| 0.580| 0.895| 0.324| 0.779|       |
| (0.040)| (0.161)| (0.000)| (0.000)| (0.000)| (0.000)| (0.000)| (0.000)| (0.000)| (0.007)| (0.000)| |
| Man      | −0.303| −0.272| 0.916    | 0.884| 0.578| 0.795| 0.708| 0.748| 0.050| 0.820|       |
|          | (0.182)| (0.234)| (0.000)| (0.000)| (0.000)| (0.000)| (0.000)| (0.000)| (0.029)| (0.000)| |

Table 5. The Spearman rank correlation analysis for growth hormone–releasing hormone (GHRH) and TNF-α, including selected variables in the general group, men and women.

| Variable | HGH  | Adiponectin | GSH  | R-GSSG | Homocysteine | IL–1α     |
|----------|------|-------------|------|--------|-------------|-----------|
|          | R(p) | R(p)        | R(p) | R(p)   | R(p)        | R(p)      |
| GHRH     |      |             |      |        |             |           |
| Total    | 0.775| 0.314       | −0.220| −0.224| −0.232      | 0.260     |
|          | (0.000)| (0.003)| (0.040)| (0.036)| (0.030)| (0.014)| |
| Woman    | 0.757| 0.286       | −0.137| −0.172| −0.173      | 0.222     |
| (0.000)| (0.019)| (0.269)| (0.163)| (0.161)| (0.072)| |
| Man      | 0.734| 0.282       | −0.256| −0.212| −0.272      | 0.279     |
| (0.000)| (0.216)| (0.263)| (0.357)| (0.234)| (0.220)| |
| TNF-α    |      |             |      |        |             |           |
| Total    | 0.397| 0.137       | 0.017| 0.301  | 0.216       | −0.422    |
|          | (0.000)| (0.198)| (0.877)| (0.004)| (0.042)| (0.000)| |
| Woman    | 0.401| 0.242       | 0.181| 0.332  | 0.234       | −0.384    |
| (0.001)| (0.045)| (0.136)| (0.005)| (0.055)| (0.001)| |
| Man      | 0.432| −0.093      | −0.465| 0.244  | 0.142       | −0.500    |
| (0.051)| (0.689)| (0.034)| (0.287)| (0.539)| (0.021)| |

FSH—follicle-stimulating hormone; HGH—human growth hormone; GSH—glutathione; CAT—chloramphenicol acetyltransferase; GST—glutathione S-transferase; SOD—superoxide dismutase.

The decline in serum LH levels in old age is accompanied by decreased in FSH levels, and this correlation was observed both among women and men. Meanwhile, women are predisposed to a significant positive relationship between LH levels and the concentrations of antioxidant enzymes (GPx, CAT, SOD, GST) and antioxidants (GSH), in addition to a negative relationship between the level of LH and those of resistin and IL-6. With respect to homocysteine, all statistically significant correlations in the analysis were positive and found in both sexes (Table 4).
Table 6. The Spearman rank correlation analysis for IL-6, including selected variables in the general group, men and women.

| Variable | LH | GST | R-GSSG | Homocysteine | TNF-α | SOD | IGF-1 | IL-1β |
|----------|----|-----|--------|--------------|-------|-----|-------|-------|
|          | R(\(p\)) | R(\(p\)) | R(\(p\)) | R(\(p\)) | R(\(p\)) | R(\(p\)) | R(\(p\)) | R(\(p\)) |
| **IL-6** |    |     |        |              |       |     |       |       |
| Total    | −0.184 (0.083) | 0.194 (0.066) | 0.236 (0.025) | 0.242 (0.021) | 0.117 (0.877) | 0.206 (0.052) | −0.062 (0.562) | −0.259 (0.014) |
| Woman    | −0.283 (0.019) | 0.260 (0.031) | 0.201 (0.383) | 0.324 (0.007) | 0.181 (0.136) | 0.257 (0.033) | −0.025 (0.840) | −0.306 (0.010) |
| Man      | 0.098 (0.674) | 0.029 (0.900) | 0.247 (0.041) | 0.050 (0.829) | 0.097 (0.034) | 0.076 (0.676) | −0.137 (0.553) | 0.005 (0.982) |

Table 7. The Spearman rank correlation analysis for follicle-stimulating hormone (FSH), glutathione S-transferase (GST), oxidized glutathione (GSSG) and glutathione reductase (R-GSSG), including selected variables in the general group, men and women.

| Variable | Resisten | GSH | GPx | CAT | GST | GSSG | R-GSSG | Homocysteine | SOD | IGF-1 | IL-10 |
|----------|---------|-----|-----|-----|-----|------|--------|--------------|-----|-------|-------|
|          | R(\(p\)) | R(\(p\)) | R(\(p\)) | R(\(p\)) | R(\(p\)) | R(\(p\)) | R(\(p\)) | R(\(p\)) | R(\(p\)) | R(\(p\)) |
| **FSH**  |        |     |     |     |     |      |       |              |     |       |       |
| Total    | −0.260 (0.013) | 0.166 (0.119) | 0.196 (0.064) | 0.175 (0.032) | 0.226 (0.038) | 0.219 (0.272) | 0.117 (0.410) | 0.088 (0.145) | 0.155 (0.064) | 0.196 (0.033) |
| Woman    | −0.376 (0.001) | 0.312 (0.009) | 0.384 (0.001) | 0.313 (0.009) | 0.302 (0.012) | 0.335 (0.024) | 0.272 (0.040) | 0.247 (0.013) | 0.298 (0.306) | 0.125 (0.047) |
| Man      | 0.135 (0.559) | −0.192 (0.404) | −0.252 (0.271) | −0.135 (0.559) | 0.132 (0.567) | −0.079 (0.733) | −0.216 (0.348) | −0.030 (0.182) | −0.257 (0.260) | 0.504 (0.020) |

**Correlation analysis of IL-6 levels and other parameters included in the analysis again demonstrated that women are more predisposed to a significant relationship between the studied parameters. Positive correlations were found for IL-6 versus SOD, GST and homocysteine, and negative correlations – for IL-6 versus LH and IL-1β (Table 6).**

Further, in the case of significant correlations between FSH (follicle-stimulating hormone) and other variables in the analysis, female gender rather than male seems to be the determining factor. With regard to other variables (GST, GSSG, R-GSSG), in the women’s group, statistically significant relationships were observed more frequently than in the men’s group. The strength of relationship for statistically significant results was similar in the representatives of both genders (Table 7).
4. Discussion

Ageing is a physiological process affecting all people. Regardless of biological and environmental changes taking place, comprehensive research may help us expand our knowledge on the mechanisms influencing longevity. Understanding the processes taking place in old age would make it possible to develop a specific antidote to ageing. The ageing process is a phenomenon leading to an emergence of a web of interrelated biological processes producing significant changes in the human body. The scientific exploration of bodily functions in old age is greatly furthered by the study of biological parameters, lending themselves to a quantitative and qualitative assessment of various conditions and phenomena presenting themselves in the ageing body. The biological factors subject to exploration are a valuable and constantly evolving source of knowledge on longevity and methods for diagnosing, treating and preventing diseases. The complex mechanisms driving the changes related to body ageing take place in cells and tissues in an imprecise and inconsistent manner. The ageing process may be delayed by lifestyle, including physical exercise, nutrition and the surrounding environment.

The available literature discussing research into the impact of changes in selected biochemical factors on long-living people is rather scarce. This area of medical science is still being studied by scholars around the world and keeps expanding to include more and more new longevity research methods. Our study was aimed at identifying changes which may occur in selected biochemical factors in very old age. Findings from these studies may help establish the molecular profile of people aged over 80 years.

4.1. Influence of Leptin and Adiponectin Levels on Longevity

In a study by Pareja-Galeano et al. [19] devoted to leptin and adiponectin levels in longevity, higher concentrations of the former were observed ($p < 0.001$) in the group of centenarians compared to the control group made up of elderly individuals, whereas no statistically significant differences were observed for adiponectin levels. It is suggested that further research should be conducted to explain the influence of high levels of proteins secreted by adipocytes on health and vitality in old age [20]. Our study confirmed that there was no correlation between adiponectin and gender ($p = 0.663$). On the other hand, the analysis of 80 obese individuals performed by Selthofer-Relatić et al., where the mean age for men was $59.47 \pm 7.60$ years, and for women $64.10 \pm 7.59$ years, demonstrated that women have a substantially higher ratio of leptin to adiponectin than men [21]. Further research in this scope is needed.

4.2. Markers of Inflammation in Longevity

The ageing process is directly related to the immune and inflammatory function, which has been confirmed by many scholars [22–24]. Hurme et al. [25] presented substantial evidence pointing to the relationship between the rate of inflammation and human longevity. Elevated concentrations of inflammation markers, i.e., TNF-α and IL-6, may lead to increased mortality rates among the elderly, thus reducing survival in this age group [22–24]. This was confirmed by Bonafe et al. [26] who demonstrated that people genetically predisposed to produce high levels of IL-6 during ageing are less likely to reach the extreme limits of the human life span, which proves that low IL-6 levels have a positive impact on longevity. Researchers were also able to demonstrate that in women, there is no correlation between high IL-6 and old-age survival, unlike in men, which may result from the inhibiting effect of oestrogens on the expression of the IL-6 gene [26]. Our own study, however, did not reveal a dependence between IL-6 and gender ($p = 0.806$). The authors, Chen CJ et al. and Prather AA et al. analyzing younger populations than the population described in our study, assert that there are differences in IL-6 levels between sexes [27,28].

Ruan et al. in their study attempted to identify the biomarkers of human ageing. They found a correlation between the activity of antioxidant enzymes SOD ($p = 0.003$), POD ($p = 0.004$), GSH-px ($p = 0.018$) and pro-inflammatory cytokine IL-6 ($p < 0.001$) with the age of the study participants.
The other parameters included in the study (IL-10, IL-1β) were not significantly correlated with age [29]. Our own findings also confirmed positive correlations between the level of IL-6 and SOD, GST (Table 6).

Cauley et al. [30], studying a population representing the 70–79 age group, proved that elevated inflammatory markers are associated with an increased risk of fractures. Moreover, Rodondi et al. [31] demonstrated that IL-6 and AAI (ankle-arm index) are associated with future coronary heart disease (CHD) events beyond traditional risk factors and modestly improve risk predictions in older adults [31]. Other studies conducted in a senior population revealed a relationship between elevated levels of IL-6, CRP and diminished cognitive function [32], as well as an increased risk of type 2 diabetes [33]. Moreover, increased serum IL-6 is more strongly, than other inflammatory markers (CRP, TNF-α), associated with the risk of disease, disability, and mortality [34]. Almeida et al. [35] found a relationship between frailty in old age and increased levels on CRP, while Tiainen et al. [36] pointed to a correlation between chronic inflammation and that condition. On the other hand, the team of Liu et al. [37] in their study of a group aged 70–84 failed to identify any relationship between these variables, while a study by Lim et al. in a group of nonagenarians found lower levels of IL-6 and THFR1 and higher levels of IGF-1 in the subgroup with the highest cognitive status [38]. All this points to the complexity of the processes taking place and the interaction between the biochemical parameters in ageing individuals, and that is why it seems necessary to continue research, taking advantage of already gathered data [39], particularly in groups of longevous individuals (Figure 1).

![Figure 1](image_url)

**Figure 1.** Relations between biochemical parameters and the supposed consequences in health and longevity.

### 4.3. Gene Expressions and Longevity

The inflammatory process in a given tissue is the body’s response to a disruption of homeostasis. Cytokines, and among them TGF-β1 responsible for regulating the immune response, may play a special role in the ageing process. Carieri et al. studied a group of centenarians (aged 99–103) with a younger control group (aged 20–60) and found significant differences in genetic variability of the
TGF-β1 gene with markedly higher plasma levels of the biologically active form of TGF-β1 in both men and women from the centenarian group. These findings point to a relationship between TGF-β1 genetic variability and longevity (Figure 2).

![Figure 2. Relationship between changes in TGF gene expression and longevity.](image)

The authors additionally noted no relationship between the age-related increase in TGF-β1 levels and specific genetic variability (p > 0.05) [40]. At the same time, numerous studies have demonstrated links between TGF-β1 polymorphism and an increased risk of certain conditions, e.g., Alzheimer’s disease [41], osteoporosis [42], or hypertension [43].

Research into polymorphisms of IL-6, IL-10 and IFN-γ carried out by Bosco et al. [41] in a group of 112 centenarians did not reveal a relationship between polymorphism and longevity in the study group. Further, Spoel et al. [44] sought to demonstrate a correlation between the serum levels of IGF-1, age and functional status in a group aged ninety years and older. Their findings in terms of IGF-1 levels failed to demonstrate any significant sex-specific differences (p = 0.98), while the concentration of IGFBP3 (insulin like growth factor binding protein 3) and IGF-1/IGFBP3 ratio demonstrated sex-dependent variability (respectively: p < 0.001; p < 0.001). At the same time, the authors found a positive correlation of the level of IGF-1 with longer life span and ability to function independently.

Longevity studies enable us to devise optimal strategies for planning care and satisfying the specific needs of the elderly population [45]. There are theories claiming that the ageing body accumulates damaged proteins and genetic material, which in consequence leads to apoptosis, chronic inflammation and age-related diseases. As a result, the changes caused by the diminished regenerative capacity and the accelerated accumulation of damage may overlap [46], hence strategies aimed at delaying the ageing process rely mainly on preventing or eliminating the damage done. There is no doubt that these mechanisms are determined by genetic, epigenetic and environmental factors. Gene variants correlated with longevity are known, and among them are those protein products involved in lipid metabolism and participate in nutrient sensing signaling pathways, such as the insulin/insulin-like growth factor (IGF-1) and mTOR pathways [47].

5. Conclusions

The aging process is extremely complex, but understanding it will allow real intervention in prolonging life. Selected biochemical parameters involved in the aging process determine changes in the human body. Research on processes related to aging and longevity will allow us to learn about the mechanisms responsible for them and enjoy these processes in good health. There is a need to conduct further research in the field of the occurrence of gender predispositions to significant dependencies in selected biochemical parameters.

**Author Contributions:** Conceptualization, P.Z. and A.J.; data curation, P.Z. and A.K.; formal analysis, I.G.; investigation, P.Z.; methodology, P.Z.; I.G. and A.L.; resources, P.Z.; S.W.-H.; I.G.; A.L.; A.K. and A.J.; writing—original draft preparation, P.Z. and S.W.-H.; writing—review and editing, A.J.

**Funding:** Financial resources for the project and funds for covering the costs to publication come exclusively from the Pomeranian Medical University of Szczecin.

**Conflicts of Interest:** The authors declare no conflict of interest.
References

1. Kulik, T.B.; Janiszewska, M.; Piróg, E.; Pacian, A.; Stefanowicz, A.; Żołnierczuk-Kieliszek, D.; Pacian, J. Sytuacja zdrowotna osób starszych w Polsce i innych krajach. Med. Ogólna Nauk. Zdrowia 2011, 17, 90–95.

2. Ludność. Stan I Struktura Demograficzno-Społeczna. Available online: https://stat.gov.pl/cps/rde/xbr/gus/LUD_ludnosc_stan_str_dem_spo_NSP2011.pdf (accessed on 12 February 2019).

3. Grzanka-Tykiwińska, A.; Kędziora-Kornatowska, K. The significance of selected forms of activity in elderly people’s lives. Gerontol. Pol. 2010, 18, 29–32.

4. Zielińska–Więcżkowska, A.; Kędziora-Kornatowska, K. The significance of selected forms of activity in elderly people’s lives. Gerontol. Pol. 2008, 16, 131–136.

5. Tsai, C.L.; Wang, C.H.; Pan, C.Y.; Chen, F.C. The effects of long-term resistance exercise on the relationship between neurocognitive performance and GH, IGF-1, and homocysteine levels in the elderly. Front. Behav. Neurosci. 2015. [CrossRef] [PubMed]

6. Kann, P.H.; Bergmann, S.; Stalla, G.K.; Dimopoulou, C.; Weber, M.M.; Pedersen, B.T.; Meckes-Ferber, S. Gender-, age- and time-dependent dosing of growth hormone in adults—Real-world data from a decade of clinical practice in Germany. Cytoke. Endocrinol. 2017, 33, 564–569. [CrossRef]

7. Drewes, Y.M.; Poortvliet, P.K.E.; Blom, J.W.; de Ruijter, W.; Wesendorp, R.G.J.; Stott, D.J.; Blom, H.J.; Ford, I.; Satter, N.; Jukema, W.; et al. Homocysteine levels and treatment effect in the prospective study of pravastatin in the elderly at risk. J. Am.Geriatr. Soc. 2014, 62, 213–221. [CrossRef] [PubMed]

8. Zang, S.; Bai, Y.Y.; Luo, L.M.; Xiao, W.K.; Wu, H.M.; Ye, P. Association between serum homocysteine and arterial stiffness in elderly: A community-based study. J. Geriatr. Cardiol. 2014, 11, 32–38. [CrossRef]

9. Izzicupo, P.; D’Amico, M.A.; Napolitano, G.; Nakamura, F.Y.; Di Baldassarre, A.; Ghinassi, B. Aerobic training improves angiogenic potential independently of vascular endothelial growth factor modifications in postmenopausal woman. Front. Endocrinol. 2017, 8, 363. [CrossRef] [PubMed]

10. Pedersen, B.K.; Fabbraio, M.A. Muscles, exercise and obesity: Skeletal muscle as a secretory organ. Nat. Rev. Endocrinol. 2012, 8, 457–465. [CrossRef]

11. Penninx, B.W.; Kritchevsky, S.B.; Yamashita, K.; Newman, A.B.; Simonsick, E.M.; Rubin, S.; Ferrucci, L.; Harris, T.; Pahor, M. Inflammatory markers and depressed mood in older person: Results from the health, aging and body composition study. Biol. Psychiatry 2003, 54, 566–572. [CrossRef]

12. Payette, C.; Blackburn, P.; Lamarche, B.; Tremblay, A.; Bergeron, J.; Lemieux, I.; Després, J.P.; Pouillart, S. Sex differences in postprandial plasma tumor necrosis factor-α, interleukin-6, and C-reactive protein concentrations. Metab. Clin. Exp. 2009, 58, 1593–1601. [CrossRef]

13. Thorleifsson, S.J.; Margretardottir, O.B.; Gudmundsson, G.; Olafsson, I.; Benediktsdottir, B.; Janson, C.; Buist, A.S.; Gislason, O. Chronic airflow obstruction markers of systemic inflammation: Results from the BOLD study in Iceland. Respir. Med. 2009, 103, 1548–1553. [CrossRef]

14. Ouchi, N.; Park, J.L.; Lugus, J.J.; Walsh, K. Adipokines in inflammation and metabolic disease. Nat. Rev. Immunol. 2011, 11, 85–97. [CrossRef]

15. Welsh, P.; Woodward, M.; Rumley, A.; Lowe, G. Associations of plasma pro-inflammatory cytokines, fibrinogen, viscosity and C-reactive protein with cardiovascular risk factors and social deprivation: The fourth Glasgow MONICA study. Br. J. Haematol. 2008, 141, 852–861. [CrossRef]

16. Kozek, E.; Klupa, T.; Witek, P.; Malecki, M.; Sieradzki, J. Fibrinogen as a coronary risk factor in patients with type 2 diabetes mellitus. Diabet. Prakt. 2003, 4, 265–271.

17. Wasilewski, J.; Poloniecki, L. Importance of fibrinogen and the rheological properties of blood in atherosclerosis and coronary artery disease. Chor. Serca. Naczyn. 2010, 7, 62–71.

18. Passowicz-Muszyńska, E.; Gostkowska-Malec, A.; Jankowska, R.; Piesiak, P. Chronic obstructive pulmonary disease and cardiovascular diseases. Pneumol. Alergil. Pol. 2010, 78, 28–32.

19. Pareja-Galeano, H.; Santos-Lozano, A.; Sanchis-Gomar, F.; Fiuza-Luces, C.; Garatachea, N.; Galvez, B.G.; Lucia, A.; Emanuele, E. Circulating leptin and adiponectin concentrations in healthy exceptional longevity. Diabetes Vasc. Dis. Res. 2018, 15, 260–262. [CrossRef]

20. Min, K.J.; Lee, C.K.; Park, H.N. The lifespan of Korean eunuchs. Curr. Biol. 2012, 22, 792–793. [CrossRef]
22. Ershler, W.B.; Keller, E.T. Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. *Ann. Rev. Med.* **2000**, *51*, 245–270. [CrossRef]

23. Franceschi, C.; Valensin, S.; Bonafe, M.; Paolissio, G.; Yashin, A.I.; Monti, D.; De Benedictis, G. The network and remodeling theories of aging: Historical background and new perspectives. *Exp. Gerontol.* **2000**, *35*, 879–896. [CrossRef]

24. Bruunsgaard, H.; Pedersen, M.; Klarlund, P.B. Aging and proinflammatory cytokines. *Curr. Opin. Hematol.* **2001**, *8*, 131–136. [CrossRef]

25. Hurmea, M.; Lehtimäki, T.; Jylhäc, M.; Karhunend, P.J.; Hervonen, A. Interleukin-6-174G/C polymorphism and longevity: A follow-up study. *Mech. Ageing Dev.* **2005**, *126*, 417–418. [CrossRef]

26. Bonafe, M.; Olivieri, F.; Cavallone, L.; Giovagnetti, S.; Marchegiani, F.; Cardelli, M.; Pieri, C.; Marra, M.; Antonicelli, R.; Lisa, R.; et al. A gender-dependent genetic predisposition to produce high levels of IL-6 is detrimental for longevity. *Eur. J. Immunol.* **2001**, *31*, 2357–2361. [CrossRef]

27. Chen, C.J.; Sung, W.W.; Lin, Y.M.; Chen, M.K.; Lee, C.H.; Lee, H.; Yeh, K.T.; Ko, J.L. Gender difference in the prognostic role of interleukin 6 in oral squamous cell carcinoma. *PLoS ONE* **2012**, *7*, e50104. [CrossRef]

28. Prather, A.A.; Carroll, J.E.; Fury, J.M.; McDade, K.K.; Ross, D.; Marsland, A.L. Gender differences in stimulated cytokine production following acute psychological stress. *Brain Behav. Immun.* **2009**, *23*, 622–628. [CrossRef]

29. Ruan, Q.; Yu, Z.; Ma, C.; Bao, Z.; Li, J.; Chen, J.; Fu, L. Age-related differences in co-morbidity number, fundus atherosclerosis level and the serum values of GSH-PX, HS-CRP and HDL-C in elderly chinese patient. *J. Aging Res. Clin. Pract.* **2016**, *5*, 43–49.

30. Cauley, J.A.; Danielson, M.E.; Boudreau, R.M.; Forrest, K.Y.Z.; Zmuda, J.M.; Pahor, M.; Tylavsky, F.A.; Cummings, S.R.; Harris, T.B.; Newman, A.B. Inflammatory markers and incident fracture risk in older men and women: The health aging and body composition study. *J Bone Miner. Res.* **2007**, *22*, 1088–1095. [CrossRef]

31. Rodondi, N.; Marques-Vidal, P.; Sutton, J.; Sutton-Tyrrell, K.; Satterfield, S.; Harris, T.; Bauer, D.C.; Ferrucci, L.; Vittinghoff, E.; et al. Markers of atherosclerosis and inflammation for prediction of coronary heart disease in older adults. *Am. J. Epidemiol.* **2010**, *171*, 540–549. [CrossRef]

32. Yaffe, K.; Lindquist, K.; Penninx, B.W.; Simonsick, E.M.; Pahor, M.; Kritchevsky, S.; Launer, L.; Kuller, L.; Rubin, S.; Harris, T. Inflammatory markers and cognition in well-functioning African-American and white elders. *Neurology* **2003**, *61*, 76–80. [CrossRef]

33. Pradhan, A.D.; Manson, J.E.; Rifai, N.; Buring, J.E.; Ridker, P.M. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. *JAMA* **2001**, *286*, 327–334. [CrossRef] [PubMed]

34. Singh, T.; Newman, A.B. Inflammatory markers in population studies of aging. *Ageing Res. Rev.* **2011**, *10*, 319–329. [CrossRef]

35. Almeida, O.P.; Norman, P.E.; van Bockxmeer, F.M.; Hankey, G.J.; Flicker, L. CRP 1846G>C polymorphism increases risk of frailty. *Maturitas* **2012**, *71*, 261–266. [CrossRef]

36. Tiainen, K.; Hurme, M.; Hervonen, A.; Luukkaala, T.; Jylhä, M. Inflammatory markers and physical performance among nonagenarians. *J. Gerontol.* **2010**, *65*, 658–663. [CrossRef]

37. Liu, Z.Y.; Wang, Z.D.; Li, L.Z.; Chu, X.F.; Zhu, Y.S.; Shi, J.M.; Xie, X.J.; Jin, L.; Wang, Y.; Wang, X.F. Association of CRP gene polymorphisms with CRP levels, frailty and co-morbidity in an elderly Chinese population: results from RuLAS. *Age Ageing* **2012**, *45*, 360–365. [CrossRef]

38. Lim, W.S.; Lim, J.P.; Tan, C.N.; Yew, S.; Leung, B.; Chong, M.S.; Lieu, P.K. Cognitive and psychological profiles in nonagenarians: Association with comorbidities, nutritional status, and blood biomarkers. *Alzheimer’s Dement.* **2018**. [CrossRef]

39. Tiainen, K.; Luukkaala, T.; Hervonen, A.; Jylhä, M. Predictors of mortality in men and women aged 90 and older: A nine-year follow-up study in the Vitality 90+ study. *Age Ageing* **2013**, *42*, 468–475. [CrossRef]

40. Carriero, G.; Marzi, E.; Olivieri, F.; Marchegiani, F.; Cavallone, L.; Cardelli, M.; Giovagnetti, S.; Steconi, R.; Molendini, C.; Trapassi, C. The G/C915polymorphism of transforming growth factor β1 is associated with human longevity: A study in Italian centenarians. *Aging Cell* **2004**, *3*, 443–448. [CrossRef]

41. Bosco, P.; Ferri, R.; Salluzzo, M.G.; Castellano, S.; Signorelli, M.; Nicoletti, F.; Nuovo, S.D.; Drago, F.; Caraci, F. Role of the transforming-growth-factor-β1 gene in late-onset alzheimer’s disease: Implications for the treatment. *Curr. Genom.* **2013**, *14*, 147–156. [CrossRef]

42. Langdahl, B.L.; Carstens, M.; Stenker, L.; Eriksen, E.F. Polymorphisms in the transforming growth factor beta 1 gene and osteoporosis. *Bone* **2003**, *32*, 297–310. [CrossRef]
43. Scaglione, R.; Argano, Ch.; Duro, G.; Chiara, T.; Nuzzo, D.; Colomba, D.; Fiore, M.C.; Corrao, S.; Licatal, G. The relationship between the transforming growth factor β1 t29c gene polymorphism and left ventricular geometry and function in hypertensive subjects. *Int. J. Hypertens.* 2010. [CrossRef]

44. van der Spoel, E.; Rozing, M.P.; Houwing-Duistermaat, J.J.; Slagboom, P.E.; Beekman, M.; de Craen, A.J.; Westendorp, R.G.; van Heemst, D. Association analysis of insulin-like growth factor-1 axis parameters with survival and functional status in nonagenarians of the Leiden Longevity Study. *Aging* 2015, 7, 956–963. [CrossRef]

45. Odden, M.C.; Koh, W.J.H.; Arnold, A.M.; Rawlings, A.M.; Psaty, B.M.; Newman, A.B. Trajectories of nonagenarian health: Sex, age, and period effects. *Am. J. Epidemiol.* 2019, 188, 382–388. [CrossRef]

46. Gladyshev, V.N. The free radical theory of aging is dead. Long live the damage theory! *Antioxid. Redox Signal.* 2014, 20, 727–731. [CrossRef]

47. Passtoors, W.M.; Beekman, M.; Deelen, J.; van der Breggen, R.; Maier, A.B.; Guigas, B.; Derhovanessian, E.; van Heemst, D.; de Craen, A.J.; Gunn, D.A.; et al. Gene expression analysis of mTOR pathway: Association with human longevity. *Aging Cell* 2013, 12, 24–31. [CrossRef]

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).